XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Compare index fund performance year by year to detect stability, volatility, and opportunities for strategic adjustments.
25,001 articlesSPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
A leading life sciences supplier has seen its stock fall sharply over the past year. At the same time, a hedge fund s...
A niche ETF that targets closed-end funds is delivering roughly 15% total return over the past year, while its holdin...
SCHD will conduct its annual reconstitution on March 23, trimming energy exposure and leaning more on financials to d...
Retiring with $1.5 million sounds like a win, but without a solid plan, it can still run dry. This guide delivers pra...
Most taxpayers overlook deductions that can trim tax bills. This complete checklist reveals hidden write-offs, simple...
Retirees face a surprising two-year lag between last-year earnings and Medicare premium changes, even when Social Sec...
Heirs can incur penalties under the year-of-death RMD rule for inherited 401(k)s. This report explains the little-kno...
International markets are shining again. This article breaks down why VYMI could be a smart addition for income-focus...
Vanguard, the $12 trillion firm, is edging into digital assets. This move could reshape access to crypto, fees, and r...
A disciplined, theme-driven ETF approach can produce returns that exceed typical expectations. Learn how to recognize...
This week's Sunday reads gather practical investing lessons you can act on. From patient investing to tax strategies,...